NCT02002182View on ClinicalTrials.gov

ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 1, 2018

Study Completion Date

August 1, 2019

Conditions
Head and Neck CancerSquamous Cell Carcinoma of the Head and NeckHPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
BIOLOGICAL

ADXS11-001 (ADXS-HPV)

ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

Advaxis, Inc.
All Listed Sponsors
collaborator

Advaxis, Inc.

INDUSTRY

lead

Andrew Sikora

OTHER

NCT02002182 - ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | Biotech Hunter | Biotech Hunter